Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Trojan Fund from Troy Asset Management Sebastian Lyon, Charlotte Yonge | “Whereas Visa's latest quarter revealed one of the strongest underlying growth rates in more than a decade, Alcon's operating performance has been less than stellar. The shares are down -14% (in GBP) year-to-date. The market's verdict is that execution has repeatedly disappointed and that the medium-term outlook for mid-to-high single digit revenue growth is no longer credible. Growth has slowed for two reasons: Stagnant implantables growth. Whilst tariffs and investment spending have had an impact on earnings in the near term, the bear case is mostly focussed on Alcon's intraocular lens (IOL) franchise for cataracts surgery. Implants account for ~17% of total group sales and the premium end of this segment is one of the highest-margin and, historically, one of the faster-growing parts of the business. Segment growth has slowed to the low-single-digits under weaker US procedure volumes and intensifying competition. With last year's soft trends recurring, investor patience is running thin. Contact lens slowdown. A secondary concern is a reduction in growth for contact lenses from the high-single digits to the mid-single digits. Market growth is weaker as pricing in European markets moderate, and Alcon's share gains have diminished as product launches mature. We share the disappointment. We also take a broader perspective. Implant competition has proven fiercer than we anticipated and category growth has unexpectedly slowed. Yet Alcon's ophthalmology portfolio is very broad, and management gets too little credit for their long track record for execution and innovation. For implantables. We expect new product launches to stabilise market share in the coming 12 months, and for new industry capacity in the US to restore category growth. Near-term implant share pressure does not change the long-run economics of owning the leading IOL franchise in a market (covering equipment, implants, and surgical consumables) with decades of growth ahead. For contacts. Underlying growth is healthier than the headlines suggest as Alcon deliberately retires older lines in favour of newer ones. We are encouraged by launches in the higher margin reusable segment, where Alcon is under-represented. Diminished pricing power is partly cyclical, following outsized 2023-2024 increases and soft consumer confidence. Alcon continues to win international share, and the industry remains a disciplined oligopoly based on patient and optician loyalty and manufacturing complexities. Elsewhere, performance is encouraging. Alcon is successfully innovating and commercialising products across surgical equipment, over the counter (OTC) and prescription medicines. It stands at the start of a 10-year cataracts surgical equipment replacement cycle, driving strong near-term equipment sales and pulling through revenue for premium-priced surgical consumables. Alcon's Ocular Health segment – OTC and prescription medicines, primarily for dry eye – is of a similar size and profitability to surgical implants and grew +10% in the latest quarter, driven by new product launches. Balancing the short term against the long term. We do not dismiss the slowdown in important ophthalmic categories or the execution risk required to address it. We also find the quality of Alcon's assets – distribution, brands, R&D engine, and position in a structurally attractive oligopoly – are intact. Trading at their historical lows, the company's share price continued disappointment and structural impairment, offering an attractive opportunity to own the global leader in ophthalmology, with the broadest product range, the deepest pipeline, and a defensible competitive position. We expect Alcon to reassert their leadership with new products, directed by a management team that has transformed and revitalised the business over the past decade via continuous reinvestment, innovation and strong execution.” | BULL | Q2 2026 Jul 10, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
